Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Hormonal strategies in gynecologic cancer: Bridging biology and therapy.

Nieves-Neira W, Kim JJ, Matei D.

Gynecol Oncol. 2018 Aug;150(2):207-210. doi: 10.1016/j.ygyno.2018.06.005. Epub 2018 Jun 20. No abstract available.

PMID:
29933928
2.

CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.

Saygin C, Wiechert A, Rao VS, Alluri R, Connor E, Thiagarajan PS, Hale JS, Li Y, Chumakova A, Jarrar A, Parker Y, Lindner DJ, Nagaraj AB, Kim JJ, DiFeo A, Abdul-Karim FW, Michener C, Rose PG, DeBernardo R, Mahdi H, McCrae KR, Lin F, Lathia JD, Reizes O.

J Exp Med. 2017 Sep 4;214(9):2715-2732. doi: 10.1084/jem.20170438. Epub 2017 Aug 24.

3.

Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why.

Lessey BA, Kim JJ.

Fertil Steril. 2017 Jul;108(1):19-27. doi: 10.1016/j.fertnstert.2017.05.031. Epub 2017 Jun 14. Review.

4.

Association of body mass index with ER, PR and 14-3-3σ expression in tumor and stroma of type I and type II endometrial carcinoma.

Peevey JF, Seagle BL, Maniar KP, Kim JJ.

Oncotarget. 2017 Jun 27;8(26):42548-42559. doi: 10.18632/oncotarget.17209.

5.

Development of a novel human recellularized endometrium that responds to a 28-day hormone treatment.

Olalekan SA, Burdette JE, Getsios S, Woodruff TK, Kim JJ.

Biol Reprod. 2017 May 1;96(5):971-981. doi: 10.1093/biolre/iox039.

6.

The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer.

Winder A, Unno K, Yu Y, Lurain J, Kim JJ.

Cancer Biol Ther. 2017 Dec 2;18(12):958-964. doi: 10.1080/15384047.2017.1281496. Epub 2017 Nov 27.

PMID:
28112582
7.

Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.

Winder AD, Maniar KP, Wei JJ, Liu D, Scholtens DM, Lurain JR, Schink JC, Buttin BM, Filiaci VL, Lankes HA, Ramirez NC, Park K, Singh M, Lieberman RW, Mannel RS, Powell MA, Backes FJ, Mathews CA, Pearl ML, Secord AA, Peace DJ, Mutch DG, Creasman WT, Kim JJ.

Cancer. 2017 Apr 1;123(7):1144-1155. doi: 10.1002/cncr.30477. Epub 2016 Dec 7.

8.

Endometrial evaluation with transvaginal ultrasonography for the screening of endometrial hyperplasia or cancer in premenopausal and perimenopausal women.

Kim MJ, Kim JJ, Kim SM.

Obstet Gynecol Sci. 2016 May;59(3):192-200. doi: 10.5468/ogs.2016.59.3.192. Epub 2016 May 13.

9.

Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells.

Lee II, Maniar K, Lydon JP, Kim JJ.

Oncogene. 2016 Sep 29;35(39):5191-201. doi: 10.1038/onc.2016.56. Epub 2016 Mar 21.

10.

Therapeutic options for management of endometrial hyperplasia.

Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R.

J Gynecol Oncol. 2016 Jan;27(1):e8. doi: 10.3802/jgo.2016.27.e8. Epub 2015 Dec 1. Review.

11.

A rare case of post-hysterectomy vault site iatrogenic endometriosis.

Choi CH, Kim JJ, Kim WY, Min KW, Kim DH.

Obstet Gynecol Sci. 2015 Jul;58(4):319-22. doi: 10.5468/ogs.2015.58.4.319. Epub 2015 Jul 16.

12.

Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth.

Pineda MJ, Lu Z, Cao D, Kim JJ.

Horm Cancer. 2015 Aug;6(4):131-41. doi: 10.1007/s12672-015-0223-4. Epub 2015 May 15.

13.

Establishment of human patient-derived endometrial cancer xenografts in NOD scid gamma mice for the study of invasion and metastasis.

Unno K, Ono M, Winder AD, Maniar KP, Paintal AS, Yu Y, Wei JJ, Lurain JR, Kim JJ.

PLoS One. 2014 Dec 26;9(12):e116064. doi: 10.1371/journal.pone.0116064. eCollection 2014.

14.

Fenretinide: a novel treatment for endometrial cancer.

Mittal N, Malpani S, Dyson M, Ono M, Coon JS, Kim JJ, Schink JC, Bulun SE, Pavone ME.

PLoS One. 2014 Oct 23;9(10):e110410. doi: 10.1371/journal.pone.0110410. eCollection 2014.

15.

Influence of AKT on progesterone action in endometrial diseases.

Lee II, Kim JJ.

Biol Reprod. 2014 Sep;91(3):63. doi: 10.1095/biolreprod.114.119255. Epub 2014 Aug 6. Review.

16.

Activated AKT pathway promotes establishment of endometriosis.

Kim TH, Yu Y, Luo L, Lydon JP, Jeong JW, Kim JJ.

Endocrinology. 2014 May;155(5):1921-30. doi: 10.1210/en.2013-1951. Epub 2014 Feb 26.

17.

Increased AKT or MEK1/2 activity influences progesterone receptor levels and localization in endometriosis.

Eaton JL, Unno K, Caraveo M, Lu Z, Kim JJ.

J Clin Endocrinol Metab. 2013 Dec;98(12):E1871-9. doi: 10.1210/jc.2013-1661. Epub 2013 Sep 24.

18.

Ligand-activated peroxisome proliferator-activated receptor β/δ modulates human endometrial cancer cell survival.

Ma JJ, Monsivais D, Dyson MT, Coon JS, Malpani S, Ono M, Zhao H, Xin H, Pavone ME, Kim JJ, Chakravarti D, Bulun SE.

Horm Cancer. 2013 Dec;4(6):358-70. doi: 10.1007/s12672-013-0157-7. Epub 2013 Aug 14.

19.

Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.

Kim JJ, Kurita T, Bulun SE.

Endocr Rev. 2013 Feb;34(1):130-62. doi: 10.1210/er.2012-1043. Epub 2013 Jan 9. Review.

20.

Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.

Pant A, Lee II, Lu Z, Rueda BR, Schink J, Kim JJ.

PLoS One. 2012;7(7):e41593. doi: 10.1371/journal.pone.0041593. Epub 2012 Jul 24.

Supplemental Content

Loading ...
Support Center